Ignite Creation Date:
2025-12-24 @ 1:00 PM
Ignite Modification Date:
2025-12-27 @ 9:35 PM
Study NCT ID:
NCT00634361
Status:
COMPLETED
Last Update Posted:
2014-05-22
First Post:
2008-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ethyl-EPA Treatment of Prodromal Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C035276', 'term': 'eicosapentaenoic acid ethyl ester'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 7}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2001-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-05', 'completionDateStruct': {'date': '2005-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-05-21', 'studyFirstSubmitDate': '2008-03-06', 'studyFirstSubmitQcDate': '2008-03-06', 'lastUpdatePostDateStruct': {'date': '2014-05-22', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-03-13', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2005-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'conversion to psychosis', 'timeFrame': 'one year'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Schizophrenia Prodrome']}, 'descriptionModule': {'briefSummary': 'This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '35 Years', 'minimumAge': '14 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* meets criteria for schizophrenia prodrome\n\nExclusion Criteria:\n\n* any lifetime antipsychotic treatment'}, 'identificationModule': {'nctId': 'NCT00634361', 'briefTitle': 'Ethyl-EPA Treatment of Prodromal Patients', 'nctIdAliases': ['NCT00237835'], 'organization': {'class': 'OTHER', 'fullName': 'Yale University'}, 'officialTitle': 'Ethyl-EPA Treatment of Prodromal Patients', 'orgStudyIdInfo': {'id': 'LA01.03.0011'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'interventionNames': ['Drug: ethyl-eicosapentaenoic acid']}], 'interventions': [{'name': 'ethyl-eicosapentaenoic acid', 'type': 'DRUG', 'otherNames': ['ethyl-EPA, an omega-3 fatty acid'], 'description': '2 mg per day', 'armGroupLabels': ['A']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Scott W Woods, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Yale University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Yale University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}